Rewriting Life

Biotech Drug Factory

A photo essay: Inside Genetech’s South San Francisco manufacturing plant

Last year, Genentech, a global leader in the manufacture of genetically engineered drugs, had sales of about $5.5 billion. A “biotech drug” is one that uses a protein to treat a particular disorder: to make its protein-based drugs, which include cancer treatments and a human growth hormone, Genentech must grow vast quantities of therapeutic proteins in host cells and then harvest them.

The company can ferment approximately 280,000 liters of cell culture at any one time at its various manufacturing plants.

This photo essay illustrates the production process at Genentech’s South San Francisco plant, from the testing and fine-tuning of manufacturing techniques, to the fermentation of cells, to the purification of drugs that will be shipped around the world.

This story is part of our March/April 2006 Issue
See the rest of the issue
Subscribe

[Click here for the images.]

Become an MIT Technology Review Insider for in-depth analysis and unparalleled perspective.
Subscribe today

Uh oh–you've read all five of your free articles for this month.

Insider Premium

$179.95/yr US PRICE

More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Premium.

  • Insider Premium {! insider.prices.premium !}*

    {! insider.display.menuOptionsLabel !}

    Our award winning magazine, unlimited access to our story archive, special discounts to MIT Technology Review Events, and exclusive content.

    See details+

    What's Included

    Bimonthly home delivery and unlimited 24/7 access to MIT Technology Review’s website.

    The Download. Our daily newsletter of what's important in technology and innovation.

    Access to the Magazine archive. Over 24,000 articles going back to 1899 at your fingertips.

    Special Discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

    First Look. Exclusive early access to stories.

    Insider Conversations. Join in and ask questions as our editors talk to innovators from around the world.

You've read of free articles this month.